Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C

Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C

Aim of the study. To compare efficacy and safety of Algeron 1.5 and 2.0 μg/kg with PegIntron in combination with ribavirin in the treatment of chronic hepatitis C and to determine therapeutic dose of Algeron.Materials and Methods. 150 adult treatment-naive patients with HCV (all genotypes)were rando...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. V. Mayevskaya, O. O. Znoyko, E. A. Klimova, S. L. Maximov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, R. A. Ivanov, Yu. N. Linkova, T. V. Chernovskaya
Format:	Article
Language:	Russian
Published:	Gastro LLC 2013-03-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	chronic hepatitis c treatment cepeginterferon alfa-2b algeron
Online Access:	https://www.gastro-j.ru/jour/article/view/1183
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Treatment of chronic hepatitis C by cepeginterferon alpha-2b in combination to ribavirin
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
by: Nayana Hitesh Patel, et al.
Published: (2023-04-01)

Ductus Venosus Doppler S/D Value Adjusted Alfa Fetoprotein Levels to Decrease False Positive Rates
by: Alptekin Tosun, et al.
Published: (2013-12-01)

Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01)

De alfa a omega: Estimación de la confiabilidad ordinal. Una guía práctica
by: Nicolás Vizioli, et al.
Published: (2022-12-01)

Pokolenie Alfa w szkole. Działania projektowo-wdrożeniowe z wykorzystaniem ICT
by: Eunika Baron-Polańczyk, et al.
Published: (2022-12-01)

The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection
by: N. D. Yuschuk, et al.
Published: (2009-02-01)

Pegilated interferon α2а in treatment of chronic hepatitis C
by: P. O. Bogomolov, et al.
Published: (2012-09-01)

The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i>
by: A. V. Lapshin, et al.
Published: (2013-03-01)

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial)
by: Marina V. Mayevskaya, et al.
Published: (2018-08-01)

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study
by: V. T. Ivashkin, et al.
Published: (2014-07-01)

The algorythm of viral hepatites B and C diagnostics and treatment
by: N. D. Yuschuk, et al.
Published: (2010-12-01)

Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy
by: K. R. Dudina, et al.
Published: (2023-02-01)

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01)

Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?
by: S. N. Batskikh
Published: (2014-10-01)

Quantitative dynamic evaluation HBsAg in blood in comparison to viral load level in patients with chronic HBV-monoinfection
by: K. R. Dudina, et al.
Published: (2011-06-01)

Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C
by: N. B. Kovaleva
Published: (2014-08-01)

Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B
by: V. T. Ivashkin, et al.
Published: (2014-09-01)

Hepatitis C diagnostics and treatment guidelines in adults
by: V. T. Ivashkin, et al.
Published: (2013-05-01)

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Published: (2023-07-01)

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)
by: M. V. Mayevskaya, et al.
Published: (2018-08-01)

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
by: November McGarvey, et al.
Published: (2015-11-01)

Hyperferritinemia at the patient with chronic hepatitis C
by: Ye. N. German, et al.
Published: (2009-02-01)

Surgical Strategy in Patients with Complete Transposition of Internal Organs in Cancer of the Biliopancreatoduodenal Zone
by: R. V. Ischenko, et al.
Published: (2023-09-01)

Acute hepatitis of non-specified etiology
by: Ye. V. Tsyganova, et al.
Published: (2011-02-01)

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study
by: D. T. Abrurakhmanov, et al.
Published: (2014-07-01)

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome
by: Kira A Cozzolino, et al.
Published: (2025-02-01)

Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association
by: V. T. Ivashkin, et al.
Published: (2016-08-01)

Principles of management of patient with asymptomatic elevation of serum aminotransferases
by: Ye. N. German, et al.
Published: (2011-02-01)

Management approach to patients with premalignant lesions of the stomach
by: V. V. Tsukanov, et al.
Published: (2013-07-01)

Ursodeoxycholic acid in complex treatment of metabolic syndrome
by: O. A. Tanchenko, et al.
Published: (2012-02-01)

Clinical guidelines of the Russian gastroenterological association and the Russian society on study of the liver on diagnostics and treatment of cholestasis
by: V. T. Ivashkin, et al.
Published: (2015-05-01)

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms
by: Nicholas L. Calistri, et al.
Published: (2025-02-01)

Polymorphism of renin — angiotensin system genes in progression of liver fibrosis in patients with chronic hepatitis C
by: O. V. Taratina, et al.
Published: (2014-08-01)

Algorithm of management of patients with acute cholestatic hepatitis (Clinical case presentation)
by: T. A. Deyeva, et al.
Published: (2011-12-01)

Prevalence and clinical aspects of Barrett’s esophagus in Khakasia republic
by: N. N. Butorin, et al.
Published: (2010-11-01)

Prevalence and risk factors of heartburn in organized population of administrative centre of Khakasia republic
by: N. N. Butorin, et al.
Published: (2010-04-01)

Infusion therapy for chronic liver diseases
by: I. A. Kurkina, et al.
Published: (2018-08-01)

Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C
by: V. T. Ivashkin, et al.
Published: (2023-06-01)